Literature DB >> 16917481

Effects of cytotoxic T lymphocyte antigen 4 (CTLA4) signaling and locally applied steroid on retinal dysfunction by recoverin, cancer-associated retinopathy antigen.

Akiko Maeda1, Tadao Maeda, Yan Liang, Melda Yenerel, David A Saperstein.   

Abstract

PURPOSE: To assess the cytotoxic T lymphocyte antigen 4 (CTLA4) pathway in the recoverin peptide (R64; AYAQHVFRSF) mouse model of cancer-associated retinopathy (CAR) and to assess the protective effects of subconjunctival triamcinalone injections in this model.
METHODS: To study the role of the CTLA4 pathway on the R64-induced mouse model of CAR, BALB/c mice were immunized with R64. The mice were further intraperitoneally treated with anti-CTLA4 antibody to get stronger immunoreaction. The development of CAR was evaluated by electroretinogram (ERG) examinations 21 days after treatment. A cytotoxicity assay was employed to detect induction of R64-specific cytotoxic T lymphocytes (CTLs). Immunoblotting to assess the development of anti-recoverin antibody and a T cell proliferation assay to determine the activity of lymphocytes against R64 were examined in two experimental groups, anti-CTLA4 antibody treated and untreated mice.To study the protective effect of subconjunctival triamcinalone in this model, mice immunized with R64 peptide and anti-CTLA4 antibody were either treated with 50 mg/kg/body weight of triamcinalone or phosphate buffered saline (PBS). These mice were assayed using ERG and histological examination 35 days after the first R64 immunization.
RESULTS: When mice were challenged with R64 peptide and anti-CTLA4 antibody, R64 peptide-specific CTLs were induced and decreased b-wave amplitudes were observed in ERG. Conversely, no CAR symptoms were detected in mice not treated with anti-CTLA4 antibody. Anti-CTLA4 antibody treatment did not give any significant differences in T cell proliferation and humoral reaction against recoverin. Subconjunctival triamcinalone treated mice show a trend toward improved survival of outer nuclear layer cell bodies, but did not show significant improvement of ERG amplitudes compared to the untreated mice.
CONCLUSIONS: Inhibition of the CTLA4 pathway is essential for the development of recoverin-induced murine CAR, suggesting that strengthening negative T cell signaling through CTLA4 may lessen the retinal degenerations in CAR-affected subjects. The positive effects of attenuation of the CTLA4 pathway must be weighed against a potential negative effect on survival since this pathway may also provide natural immunotherapy against the underlying malignancy. Subconjunctival injections of triamcinalone may have beneficial effects on the integrity of the outer nuclear layer (ONL) of the retina in the CAR model, although there was no significant effect on the ERG recordings.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16917481

Source DB:  PubMed          Journal:  Mol Vis        ISSN: 1090-0535            Impact factor:   2.367


  6 in total

Review 1.  Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets.

Authors:  Peter J Bugelski; Pauline L Martin
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

2.  Association of secondhand smoke exposures with DNA methylation in bladder carcinomas.

Authors:  Charlotte S Wilhelm-Benartzi; Brock C Christensen; Devin C Koestler; E Andres Houseman; Alan R Schned; Margaret R Karagas; Karl T Kelsey; Carmen J Marsit
Journal:  Cancer Causes Control       Date:  2011-06-10       Impact factor: 2.506

3.  Intravenously administered anti-recoverin antibody alone does not pass through the blood-retinal barrier.

Authors:  Jeong Hun Kim; Jin Hyoung Kim; Dong Hun Kim; Woong-Yang Park; Kyu-Won Kim; Young Suk Yu
Journal:  Korean J Ophthalmol       Date:  2011-05-24

4.  Cancer-associated retinopathy preceding the diagnosis of cancer.

Authors:  Florence Hoogewoud; Pauline Butori; Philippe Blanche; Antoine P Brézin
Journal:  BMC Ophthalmol       Date:  2018-11-03       Impact factor: 2.209

Review 5.  Ocular Paraneoplastic Syndromes.

Authors:  Joanna Przeździecka-Dołyk; Anna Brzecka; Maria Ejma; Marta Misiuk-Hojło; Luis Fernando Torres Solis; Arturo Solís Herrera; Siva G Somasundaram; Cecil E Kirkland; Gjumrakch Aliev
Journal:  Biomedicines       Date:  2020-11-10

Review 6.  Are Anti-Retinal Autoantibodies a Cause or a Consequence of Retinal Degeneration in Autoimmune Retinopathies?

Authors:  Grazyna Adamus
Journal:  Front Immunol       Date:  2018-04-16       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.